Tenidap

The Lancet

Volumn 346, Issue 8973, 1995, Pages 481-485

  Madhok, R ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; CYTOKINE; GOLD; HYDROXYCHLOROQUINE; LITHIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENYTOIN; PIROXICAM; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; TENIDAP; THIAZIDE DIURETIC AGENT; WARFARIN;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE COST; HUMAN; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; LIFE EXPECTANCY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0029155425     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)91326-2     Document Type: Article

References (23)

1. Introduction: updating a reassessment of traditional paradigms concerning rheumatoid arthritis
2. The economic impact of rheumatoid arthritis
3. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient
4. Use of short-term efficacy/toxicity tradeoffs to select second line-drugs in rheumatoid arthritis a meta anaylsis of published trials
5. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta analysis
6. A multi-centre double-blind randomized trial of low dose cyclosporin and placebo therapy in combination with methotrexate in patients with severe rheumatoid arthritis
7. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts and acute phase reactants
8. The relative toxicity of disease-modifying antirheumatic drugs
9. Rheumatoid arthritis: pathophysiology and implications for therapy
10. Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclooxygenase?
11. Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase
12. Inhibition of both 5-lipoxygenase (5-LO) and cyclooxygenase (CO) pathways or arachidonic acid (AA) metabolism by CP-66,248, a novel antiinflammatory compound
13. Inhibition of neutrophil superoxidase production by tenidap is a post guanine nucleotide binding (G)protein effect
14. The inhibitory effect of tenidap on leukocyte-endothelial cell adhesion
15. Gold therapy lowers serum IL-6 levels
16. Tenidap effectively reduces cytokine synthesis and expression by human rheumatoid arthritis synovium
17. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response
18. Tenidap modulates cytoplasmic pH and inhibits anion transport in-vitro. II. Inhibition of IL-1 beta production from ATP-treated monocytes and macrophages
19. The pharmacokinetics of tenidap sodium. Br J Clin Pharmacol
20. Tenidap a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis
21. Tenidap versus naproxen in the treatment of rheumatoid arthritis
22. The effects of a 3- substituted 2-oxindole (Tenidap) on a serum marker of cartilage degradation in osteoarthritis